Indaptus Therapeutics (NASDAQ:INDP) Posts Earnings Results, Beats Estimates By $0.03 EPS

Indaptus Therapeutics (NASDAQ:INDP) announced its quarterly earnings results on Thursday. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03, Zacks reports.

Indaptus Therapeutics Price Performance

Indaptus Therapeutics stock opened at $0.81 on Friday. The stock has a market capitalization of $11.37 million, a price-to-earnings ratio of -0.47 and a beta of 1.60. Indaptus Therapeutics has a 1-year low of $0.70 and a 1-year high of $3.10. The business has a fifty day moving average price of $0.86 and a 200-day moving average price of $1.08.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.